Systematic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: To estimate the level of agreement and positivity rates of latent tuberculosis infection (LTBI) tests prior to the use of tumor necrosis factor (TNF) inhibitors in relation to underlying rheumatic diseases and endemic tuberculosis levels. Methods: The Ovid-Medline, Embase, and Cochrane Libraries were searched for articles before October 2013 involving LTBI screening in rheumatic patients, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and psoriatic arthritis. Results: In pooled analyses, 5,224 rheumatic patients had undergone both a tuberculin skin test (TST) and an interferon-gamma release assay (IGRA) before TNF inhibitors use. The positivity of TST, QuantiFERON-TB Gold In Tube (QFTGIT), and T-SPOT.TB (T-SPOT) tests were estimated to be 29%, 17%, and 18%, respectively. The agreement percentage between the TST and QFT-GIT, and between the TST and T-SPOT were 73% and 75%. Populations from low-to-moderate endemic TB presented with slightly less agreement (71% between TST and QFT-GIT, and 74% between TST and T-SPOT) than patients from high endemic countries (73% between TST and QFT-GIT, and 81% between TST and T-SPOT). By underlying disease stratification, a lower level of agreement between TST and QFT-GIT was found among AS (64%) than among JIA (77%) and RA patients (73%). Conclusions: We reaffirm the current evidence for accuracy of LTBI test done by TST and IGRA among rheumatic patients is inconsistent. Our stratified analysis suggests different screening strategies might be needed in clinical settings considering the endemic status in the patient’s country of origin and the precise nature of underlying diseases.
Abstract
Background/Aims: To estimate the level of agreement and positivity rates of latent tuberculosis infection (LTBI) tests prior to the use of tumor necrosis factor (TNF) inhibitors in relation to underlying rheumatic diseases and endemic tuberculosis levels. Methods: The Ovid-Medline, Embase, and Cochrane Libraries were searched for articles before October 2013 involving LTBI screening in rheumatic patients, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and psoriatic arthritis. Results: In pooled analyses, 5,224 rheumatic patients had undergone both a tuberculin skin test (TST) and an interferon-gamma release assay (IGRA) before TNF inhibitors use. The positivity of TST, QuantiFERON-TB Gold In Tube (QFTGIT), and T-SPOT.TB (T-SPOT) tests were estimated to be 29%, 17%, and 18%, respectively. The agreement percentage between the TST and QFT-GIT, and between the TST and T-SPOT were 73% and 75%. Populations from low-to-moderate endemic TB presented with slightly less agreement (71% between TST and QFT-GIT, and 74% between TST and T-SPOT) than patients from high endemic countries (73% between TST and QFT-GIT, and 81% between TST and T-SPOT). By underlying disease stratification, a lower level of agreement between TST and QFT-GIT was found among AS (64%) than among JIA (77%) and RA patients (73%). Conclusions: We reaffirm the current evidence for accuracy of LTBI test done by TST and IGRA among rheumatic patients is inconsistent. Our stratified analysis suggests different screening strategies might be needed in clinical settings considering the endemic status in the patient’s country of origin and the precise nature of underlying diseases.
참고문헌 (31)
- Bouza E, "Infections in systemic lupus erythematosus and rheumatoid arthritis", Infect Dis Clin North Am, 15, pp.335~361 (2001)
- Ledingham J, "British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments", Rheumatology (Oxford), 44, pp.1205~1206 (2005)
- Mariette X, "French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers", Ann Rheum Dis, 62, pp.791~ (2003)
- Singh JA, "2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis", Arthritis Care Res (Hoboken), 64, pp.625~639 (2012)
- Camlar SA, "Performance of tuberculin skin test and interferon gamma assay for the diagnosis of latent tuberculosis infection in juvenile idiopathic arthritis", Clin Rheumatol, 30, pp.1189~1193 (2011)
- Chang B, "Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea", Clin Rheumatol, 30, pp.1535~1541 (2011)
- Chen DY, "Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay", Ann Rheum Dis, 71, pp.231~237 (2012)
- Ponce de Leon D, "Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB)infection in patients with rheumatoid arthritis in a TBendemic population", J Rheumatol, 35, pp.776~781 (2008)
- Hatemi G, "QuantiFERON-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists", Arthritis Res Ther, 14, pp.R147~ (2012)
- Hsia EC, "Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis", Arthritis Rheum, 64, pp.2068~2077 (2012)
- Klein M, "QuantiFERON TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents", Clin Exp Rheumatol, 31, pp.111~117 (2013)
- Kim JH, "Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases", Semin Arthritis Rheum, 42, pp.424~432 (2013)
- Marques CD, "Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis", Rheumatol Int, 30, pp.57~62 (2009)
- Mariette X, "Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy", Ann Rheum Dis, 71, pp.1783~1790 (2012)
- Martin J, "Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis", Ann Rheum Dis, 69, pp.181~185 (2010)
- Minguez S, "Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment", Clin Rheumatol, 31, pp.785~794 (2012)
- Paluch-Oles J, "Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-α agents", Arch Med Sci, 9, pp.112~117 (2013)
- Ringrose JS, "Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy", Clin Exp Rheumatol, 29, pp.790~794 (2011)
- Saidenberg-Kermanac’h N, "Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting", Int J Tuberc Lung Dis, 16, pp.1307~1314 (2012)
- Scrivo R, "Serial interferon-γrelease assays for screening and monitoring of tuberculosis infection during treatment with biologic agents", Clin Rheumatol, 31, pp.1567~1575 (2012)
- Shovman O, "QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study", Int J Tuberc Lung Dis, 13, pp.1427~1432 (2009)
- Vassilopoulos D, "Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment", J Rheumatol, 35, pp.1271~1276 (2008)
- Vassilopoulos D, "Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy", Clin Vaccine Immunol, 18, pp.2102~2108 (2011)
- Xie X, "A T-cellbased enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy", Clin Exp Med, 11, pp.155~161 (2011)
- Ruan Q, "Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis", Clin Rheumatol, 35, pp.417~425 (2016)
- Pouchot J, "Reliability of tuberculin skin test measurement", Ann Intern Med, 126, pp.210~214 (1997)
- Menzies D., "Interpretation of repeated tuberculin tests:boosting, conversion, and reversion", Am J Respir Crit Care Med, 159, pp.15~21 (1999)
- Iannone F, "Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations", J Rheumatol Suppl, 91, pp.41~46 (2014)
- Beglinger C, "Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy", Swiss Med Wkly, 137, pp.620~622 (2007)
- Park JH, "Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial", J Rheumatol, 36, pp.2158~2163 (2009)
- Vanhoof J, "High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors", Ann Rheum Dis, 62, pp.1241~1242 (2003)